---
title: "Why Wall Street can't get enough of this dividend king"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293825844.md"
description: "AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend."
datetime: "2026-07-25T15:30:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293825844.md)
  - [en](https://longbridge.com/en/news/293825844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293825844.md)
---

# Why Wall Street can't get enough of this dividend king

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Better dividend king to buy right now: AbbVie or Johnson & Johnson?](https://longbridge.com/en/news/293843937.md)
- [Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial](https://longbridge.com/en/news/293659753.md)
- [Meet the dividend king stock that yields more than triple the S&P 500. Here's why it's a buy before the end of July](https://longbridge.com/en/news/293958219.md)
- [3 high-yielding dividend stocks worth loading up on now (1 yields over 5.5%)](https://longbridge.com/en/news/293847193.md)
- [T Rowe Price has increased its dividend for 40 consecutive years and yields 4.4%. Is the payout a bargain or a value trap?](https://longbridge.com/en/news/293591366.md)